Denali Therapeutics Inc. (NASDAQ: DNLI) reported Q4 EPS of ($0.86), $0.06 worse than the analyst estimate of ($0.80).

For earnings history and earnings-related data on Denali Therapeutics Inc. (DNLI) click here.